Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents

Article abstract of DOI:10.1021/acschemneuro.8b00524

Methcathinone analogs are appearing on the clandestine market at a rate nearly out-pacing the ability of investigators to examine them on an individual basis. To formulate structure-activity relationship (SAR) generalities, we examined the releasing ability of several simple methcathinone analogs at the three monoamine transporters (i.e., the dopamine, norepinephrine, and serotonin transporters, DAT, NET, and SERT, respectively) using in vitro assay methods. The analogs included methcathinone and 14 other compounds monosubstituted at the 2-, 3-, or 4-position. In general, (a) the 2-substituted analogs were less potent than either the 3- or 4-substituted analogs, (b) the 3- and 4-substituted analogs were relatively similar in potency, (c) methcathinone was the most selective as a DAT-releasing agent, and (d) the 3- and 4-CF₃ analogs were the least DAT-selective. For the 15 compounds, there was a significant correlation (r > 0.9) between DAT and NET potency, suggesting relatively similar structure-activity relationships (at least for the compounds examined here). Several of the compounds have appeared on the clandestine market since our studies were initiated, and the present results provide new information on how they might act.

Full text of DOI:10.1021/acschemneuro.8b00524

Subscriber access provided by RMIT University Library
Article
Systematic structure-activity studies on selected 2-, 3-, and 4-monosubstituted
synthetic methcathinone analogs as monoamine transporter releasing agents
Donna Walther, Abdelrahman R. Shalabi, Michael H Baumann, and Richard A. Glennon
ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.8b00524 • Publication Date (Web): 24 Oct 2018
Downloaded from http://pubs.acs.org on October 24, 2018
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.

Page 1 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
Systematic structure-activity studies on selected 2-, 3-, and 4-
monosubstituted synthetic methcathinone analogs as monoamine
transporter releasing agents
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Donna Walther,1 Abdelrahman R. Shalabi,2 Michael H. Baumann,1 and
Richard A. Glennon2*
1Designer Drug Research Unit, Intramural Research Program, National Institute on Drug
Abuse, National Institutes of Health, Baltimore, MD 21224, USA
2Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth
University, Richmond, Virginia 23298 USA
*Corresponding author
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 2 of 25
1
2
3
4
Abstract
5
6
7
8
Methcathinone analogs are appearing on the clandestine market at a rate nearly out-
pacing the ability of investigators to examine them on an individual basis. In order to
formulate structure-activity relationship (SAR) generalities, we examined the releasing
ability of several simple methcathinone analogs at the three monoamine transporters
(i.e., the dopamine, norepinephrine, and serotonin transporters, DAT, NET, and SERT,
respectively) using in vitro assay methods. The analogs included methcathinone, and
14 other compounds mono-substituted at either the 2-, 3-, or 4-position. In general, a)
the 2-substituted analogs were less potent than either the 3- or 4-substituted analogs, b)
the 3- and 4-substituted analogs were relatively similar in potency, c) methcathinone
was the most selective as a DAT releasing agent, and d) the 3- and 4-CF3 analogs were
the least DAT-selective. For the 15 compounds, there was a significant correlation (r >
0.9) between DAT and NET potency suggesting relatively similar structure-activity
relationships (at least for the compounds examined here). Several of the compounds
have appeared on the clandestine market since our studies were initiated and the
present results provide new information on how they might act.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
KEYWORDS: DAT, NET, SERT, Synthetic cathinones, Drug abuse, Synaptosomes
ACS Paragon Plus Environment

Page 3 of 25
ACS Chemical Neuroscience
1
2
3
4
INTRODUCTION
5
6
7
8
Over the last several years, >150 methcathinone (1) analogs, or “synthetic cathinones”
have appeared on the clandestine market as abused substances.1,2 They vary with
respect to their terminal amine substituents, length and nature of their -alkyl group,
and aryl substitution pattern. In theory, many more synthetic cathinone analogs are
possible. Some synthetic cathinones behave, primarily, as central stimulants, and a few
have been controlled as U.S. Schedule I substances.2 Yet, many more remain to be
pharmacologically and mechanistically characterized. Their pharmacological actions
can vary from agent to agent, and synthetic cathinones cannot be considered as being
an homogeneous group of similar-acting agents.1 Those synthetic cathinones bearing a
bulky terminal amine substituent and/or an extended -alkyl side chain are fairly
selective reuptake inhibitors (i.e., blockers) at membrane dopamine and norepinephrine
transporters (DAT and NET, respectively).Reviewed: 3 Agents with an N-methyl terminal
amine and an -methyl substituent, termed here as “simple methcathinone analogs”,
typically behave as DAT and NET releasing agents (i.e., substrates), but some also act
as releasing agents at the serotonin transporter (SERT) depending upon the nature of
their 4-position aryl substituent.1,3,4
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The appearance on the illicit market of so many synthetic cathinones is out-pacing the
ability of investigators (and law enforcement officials) to examine them on an individual
basis. An approach we have previously used to circumvent this problem is to
systematically examine small sets of methcathinone analogs that vary with regard to
specific substituents at a specific location to formulate structure-activity relationship
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 4 of 25
1
2
3
4
5
6
7
8
9
(SAR) generalities that might be useful to better understand larger groups of agents –
including agents that have yet to appear on the “street”. In the present investigation, we
further define the SAR of simple N-methyl cathinone or methcathinone analogs (i.e.,
cathinone analogs that possess an N-methyl and -methyl group).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH3
HN
HN
HN
HN
O
O
O
O

R
2
2
3
3
R
4
4
R
1
2a
2b
2c
2d
3a
4a
4b
4c
4d
4e
R = Cl
R = Br
R = Me
R = Cl
R = Br
R = Cl
R = Br
R = Me
R = OCH3
R = CF3
3b
3c
3d
3e
R = Me
R = OCH3
R = CF3
R = OCH3
Methcathinone (1) itself, as well as a number of other simple methcathinone analogs,
act as releasing agents (i.e., as substrates) at DAT and NET.1-3 However, variation of
the aryl 4-position substituent not only influences methcathinone potency, but can shift
action from a relatively selective DAT vs SERT releaser, to a much less DAT versus
SERT-selective agent, and even to agents with some selectivity for SERT.4 For
example, methcathinone (1) displays greater >300-fold selectivity for DAT vs SERT as a
releasing agent (see Table 1 for reference), whereas the 4-trifluoromethyl analog of
methcathinone (i.e., 4e) displays 14-fold SERT selectivity.4 In an attempt to better
understand the role of 4-position substituents on potency and selectivity, we conducted
a quantitative structure-activity relationship (QSAR) study and found that SERT better
accommodates bulky 4-position substituents than does DAT.5 That is, methcathinone
ACS Paragon Plus Environment

Page 5 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
analogs with small 4-position substituents are selective releasing agents at DAT, but as
the size of the 4-position substituent is increased, selectivity shifts in favor of SERT.5
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Here, we investigate a series of 2- and 3-substituted methcathinone analogs (i.e., 2a-d
and 3a-e, respectively) to determine their potency and selectivity as releasing agents at
DAT and SERT with the intent of conducting a QSAR study much in the same way we
examined the 4-substituted analogs.5 Furthermore, we examined each of the
compounds for their actions at NET; we have not previously reported NET release data
for 4a-4e.
SYNTHESIS
Compounds 1, 3a, and 4a-4e as their water-soluble HCl salts were on-hand from earlier
studies4,6 Some of the products and/or intermediates also have been reported by others,
but none of the synthetic targets was prepared as shown in Scheme 1.
Scheme 1. Synthesis of 2- and 3-substituted methcathinone analogs.a
CH3
CH3
CH3
CH3
Br
HN
N
O
O
O

CH3
2
R
2
R
ii
i
R
3
3
5a
5b
5c
5d
7a
2a
2b
2c
2d
R = 2-Cl
R = 2-Br
R = 2-Me
R = 2-Cl
R = 2-Br
R = 2-Me
R = 2-Cl
R = 2-Br
R = 2-Me
R = 2-OCH3
7b
7c
7d
R = 2-OCH3
R = 2-OCH3
6b
6c
6d
8b
8c
8d
8e
3b
3c
3d
3e
R = 3-Br
R = 3-Me
R = 3-OCH3
R = 3-Br
R = 3-Br
R = 3-Me
R = 3-OCH3
R = 3-CF
R = 3-Me
R = 3-OCH3
R = 3-CF3
ACS Paragon P3lus Environment

ACS Chemical Neuroscience
Page 6 of 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Reaction of bromopropiophenones 5a-d and 6b-d with N-benzyl-N-methylamine
provided N-benzyl analogs 7a-d and 8b-d, respectively. Deprotection by treatment with
1-chloroethyl chloroformate afforded targets 2a-d and 3b-d. Compound 3e was
prepared in the same manner from the known 8e. The synthesis of 3b is described in
the Methods section; all other targets were obtained using comparable reaction
aReagents and conditions: (i) N-benzyl-N-methylamine, THF, reflux, 18–23 h; (ii) (a)
conditions.
1-chloroethyl chloroformate, CH2Cl2, reflux, 2 h; (b) CH3OH, reflux, 1 h; (c) Et2O,
room temperature, 18 h.
RESULTS
The potency of methcathinone (1) as a releasing agent at DAT and NET was found to
be similar (EC50 = 21-25 nM; Table 1), and comparable, to its previously reported
potency as a DAT releasing agent.4 Its potency as a releasing agent at SERT was
substantially lower (i.e., by 100- to >300-fold; see Table 1). Representative plots for
methcathinone (1) and several 3-substituted methcathinone analogs are shown in
Supporting Information (Figure S1).
4-Substituted Analogs. DAT and SERT release potencies have been previously
reported by us for 1 and 4a-4e4 and are reproduced in Table 1 for comparison with the
ACS Paragon Plus Environment

Page 7 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
new NET release data. NET potency for these compounds appeared to co-vary with
their DAT potency (correlation coefficient r > 0.9; n = 6).
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2-Substituted Analogs. In general, where comparisons could be made, the 2-substituted
analogs displayed approximately 2- to 10-fold reduced potency at DAT than their
corresponding 4-substituted counterparts (Table 1). Potencies at NET closely mirrored
potencies at DAT (r > 0.9; n = 5). 2-Substituted methcathinone analogs showed reduced
potencies at SERT as compared to DAT release, and were from 4- to 47-fold lower than
their corresponding 4-substituted analogs.
3-Substituted Analogs. We previously reported the potency of 3a as a DAT, NET, and
SERT releasing agent (EC50 = 29, 40, and 212 nM, respectively).6 The current study
provided comparable values (EC50 = 26, 19, and 211 nM) (Table 1). As with data for
the 4-substituted and 2-substituted series, potencies of the 3-substituted analogs at
DAT mirrored their potency at NET (r > 0.9; n = 6). In general, the potencies of the 3-
substituted compounds as DAT releasing agents were 2- to 5-fold higher than those of
their corresponding 4-substituted counterparts whereas, in contrast, potencies at SERT
were consistency lower by about half, and only spanned a 5-fold range from the most
potent (i.e., 3b) to the least potent (3d).
As with the 4-substituted methcathinone derivatives (i.e., analogs 4), the high DAT
potency of the 3-substituted analogs was associated with an unsubstituted ring (i.e., 1).
However, whereas the 4-Cl, 4-Br, and 4-Me analogs 4a-4c, respectively, showed
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 8 of 25
1
2
3
4
5
6
7
8
9
several-fold reduced potency relative to methcathinone (1), their 3-substituted
counterparts were very similar in potency to the parent. Nevertheless, as seen in the 4-
substituted series, the 3-OMe and 3-CF3 analogs 3d and 3e, respectively, were the
least potent.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ACS Paragon Plus Environment

Page 9 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
Table 1. Potencies of aryl-substituted methcathinone analogs on transporter-mediated release in rat brain synaptosomes.a
7
8
9
CH3
HN
O
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
CH3
2
R
3
4
EC50 nM (SD)
2-Substituted:
3-Substituted:
4-Substituted:b
DAT
NET
SERT
DAT vs SERT
Selectivityc
DAT
NET
SERT
DAT vs SERT
Selectivityc
279
DAT
NET
SERT DAT vs SERT
Selectivityc
H (1)
Cl
Br
Me
25 (3)
179 (22)
23 (2)
93 (6 )
2592 (1000)
2815 ( 620)
103
16
4
21 (3)
22 (3)
5853 (1250)
211 (33)
136 (24)
268 (25)
683 (92)
281 (57)
12.5
22 (4)
44 (9)
100 (16)
63 (16)
111 (24)
900 (300)
3860
144
60
118
120
190
309
3.4
26 (4)
21 (3)
28 (6)
19 (3)
25 (4)
27 (4)
8
6
10
6
42.2
59.4
49.1
650 (80 ) 156 (12 ) 2837 (260)
81 ( 8) 53 ( 4 ) 490 ( 15)
1.0
2.4
0.24
0.07
6
8
OMe 920 ( 30 ) 339 ( 12) 7220 ( 900)
CF3
109 (18) 111 (12)
714 (73) 370 (49)
506
2700
-
-
-
0.4
aAll data are expressed as mean ± SD for n = 3 experiments performed in triplicate.
bDAT and SERT data previously published.4
cSERT EC50  DAT EC50
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 10 of 25
1
2
3
4
DISCUSSION
5
6
7
8
We have now examined a number of 2-, 3-, and 4-substituted simple methcathinone
analogs in a fairly systematic manner at the three monoamine transporters (present
investigation and reference 4). Each compound examined was a releasing agent at
DAT, NET, and SERT. In general, the agents (n = 15) displayed similar potencies at
DAT and NET (Figure 1). However, such a relationship was not apparent when DAT
pEC50 values were plotted against SERT pEC50 values (r = 0.209, n = 15; data not
shown). Hence, aryl substitution had a decided influence on DAT/NET versus SERT
potency and selectivity.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8.0
7.5
7.0
6.5
6.0
5.5
5.5
6.0
6.5
7.0
7.5
8.0
DAT pEC50
Figure 1. A comparison of DAT and NET release potencies for compounds shown in
Table 1 (n = 15, r = 0.950); DAT and NET data for methcathinone were only considered
once, IC50 = 21 and 22 nM, respectively).
As releasing agents, methcathinone analogs with substituents at the 2-position (i.e. 2
analogs) were not as potent as their 3- or 4-positional isomers (i.e., 3 and 4 analogs,
respectively). This is particularly true at SERT where, with one exception, 2c, EC50
ACS Paragon Plus Environment

Page 11 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
values are in the µM range. Given this trend, we did not examine the 2-CF3 analog. In
fact, a prior investigation had already demonstrated that the 2-CF3 analog of
methcathinone to be >10-fold less potent than 3e as a releasing agent at DAT and
SERT.7 In contrast, with the exception of the OMe and CF3 analogs 3d and 3e,
substituents at the 3-position had little effect on the potency of substituted
methcathinone analogs at DAT and NET, but decreased potency at SERT, relative to
their 4-substituted counterparts.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
On the basis of functional QSAR studies, we found that there are limitations to the
amount of steric bulk associated with the 4-position of simple methcathinone analogs
tolerated by DAT as releasing agents.5 In the present investigation, this same trend was
evident with the 3-substituted analogs; however, due the narrow potency range, a
QSAR study was not feasible here for these compounds. That is, four of the analogs
(i.e., 3a-3d) showed only a 4-fold range in potency, and the entire range in potency was
only 34-fold (when 3e is considered). Nevertheless, the two lowest potency compounds
as DAT releasing agents are the 3-OMe and 3-CF3 analogs 3d and 3e, which are the
two largest analogs (or analogs with the largest 3-position substituents) of those
examined. Regardless of the steric metric employed (see Supporting Information for a
comparison of modified steric E’s values, Charton’s steric parameter , and the Kier
third-order steric shape index 3 for the described substituents, and the calculated
volume of the molecules as a whole), the 3-OMe and 3-CF3 groups appear to be the
most bulky.
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 12 of 25
1
2
3
4
5
6
7
8
9
DAT does not readily accommodate large substituents at the aryl 4-position of the
simple methcathinones as releasing agents;5 this seems to be echoed here by the
findings with 3-position substituents (although no QSAR studies were conducted due to
the constricted findings). Nevertheless, it would seem that DAT does not appreciate
steric bulk on or around the 3- or 4-position of the simple methcathinone analogs as
DAT releasing agents; that is, as bulk around the 3- or 4-position increases, DAT
release potency decreases. This is not unreasonable considering that these are
adjacent positions.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The abuse character of 4-substituted methcathinone analogs has been described;1,4
but, much less is known about the 2- and 3-substituted compounds shown in Table 1. 3-
Chloromethcathinone (3a) has been found on the clandestine market,8 and has been
demonstrated to be a releasing agent at DAT/NET > SERT.9 Likewise, there have been
seizures of 3-bromomethcathinone (3b).10 3-Bromomethcathinone (3b) acts as a
reuptake inhibitor at NET and SERT (IC50 = 158 and 2,000 nM, respectively)11 at
concentrations higher than those reported here for neurotransmitter release. Because
releasing agents can behave as reuptake inhibitors at high concentrations,6 the present
results suggest that 3b might produce its effects primarily as a releasing agent. 2-
Methylmethcathinone (2c) and, especially, its positional isomer, 3-methylmethcathinone
(3c), are fast becoming two of the most popular synthetic cathinones in Europe.12-16
Compound 3c has been reported to be a reuptake inhibitor at DAT, NET, and SERT
(IC50 = 2,600, 270, and 9,500 nM, respectively)14 at concentrations well above those
shown here to serve as a releasing agent at all three transporters.
ACS Paragon Plus Environment

Page 13 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
In conclusion, 2-substituted methcathinone analogs are not well tolerated by DAT, NET,
and SERT as determined by their reduced potency as releasing agents; however, the 3-
substituted analogs are nearly equivalent in potency to their 4-substituted counterparts
as DAT and NET releasing agents, but somewhat less potent at SERT. As a
consequence, the 3-substituted analogs are slightly more DAT selective than the
corresponding 4-substituted compounds. Nevertheless, none is as selective for
DAT/NET versus SERT as is methcathinone (1) itself. Also, there is no discernable
difference in DAT and NET release potencies suggesting a similar SAR for the simple
methcathinone analogs at these two transporters. A final, yet unintended, consequence
of the present investigation was to shed light on the transporter actions of some newer
agents currently found on the clandestine market.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 14 of 25
1
2
3
4
METHODS
5
6
7
8
Synthesis. A Thomas-Hoover melting point apparatus was used for the determination
of melting points and the values are uncorrected. A Bruker ARX 400 MHz spectrometer
was used for recording 1H NMR spectra with tetramethylsilane (TMS) as an internal
standard and IR spectra were obtained using a Thermo Nicolet iS10 FT-IR. Elemental
analysis was performed by Atlantic Microlab Inc. (Norcross, GA) and observed values
were within 0.4 % of theory. A CombiFlash Companion/TS (Telodyne Isco Inc., Lincoln,
NE) was used for automated flash chromatography. Silica Gel (230-400 mesh) was
used as adsorbent, and RediSep Rf Normal-phase Silica Flash Columns (Teledyne Isco
Inc., Lincoln, NE) were used as the stationary phase. Thin-layer chromatography on
silica gel GHLF plates (250 μ, 2.5 × 10 cm; Analtech Inc., Newark, DE) was used for
monitoring reactions. Note: Although all compounds described here are methcathinone
analogs, this section identifies them by their correct chemical names.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1-(3-Bromophenyl)-2-(methylamino)propan-1-one Hydrochloride (3b).N-Benzyl-
N-methylamine (0.6 mL, 5 mmol) was added at room temperature to a stirred solution of
6b17 (0.67 g, 2 mmol) in anhydrous THF (10 mL). The stirred reaction mixture was
heated at reflux for 18 h, allowed to cool to room temperature, and solvent was removed
under reduced pressure. The residue was dissolved in EtOAc (20 mL), washed with
saturated NaHCO3 solution (5 mL), H2O (5 mL), brine (5 mL), dried (Na2SO4), and
evaporated to dryness under reduced pressure to yield a crude product that was
purified by column chromatography (silica gel; hexane/EtOAc; 95:5) to afford 0.28 g
(36%) of 8b as a yellow oil. 1H NMR (CDCl3) δ 1.22 (d, 3H, CH3), 2.11 (s, 3H, CH3),
ACS Paragon Plus Environment

Page 15 of 25
ACS Chemical Neuroscience
1
2
3
4
3.56 (s, 2H, CH2), 4.13 (q, 1H, CH), 7.16−7.26 (m, 6H, ArH), 7.59 (d, 1H, ArH), 7.82 (d,
5
6
1H, ArH), 8.09 (t, 1H, ArH).
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1-Chloroethyl chloroformate (0.2 mL, 2.0 mmol) was added at room temperature to a
stirred solution of 8b (0.28 g, 0.8 mmol) in anhydrous CH2Cl2 (5 mL). The stirred
reaction mixture was heated at reflux for 2 h, cooled to room temperature, and
concentrated under reduced pressure. The residue was dissolved in CH3OH (5 mL),
heated at reflux for 1 h, cooled to room temperature, and evaporated to dryness under
reduced pressure. The residue was stirred in Et2O for 18 h. The solid material was
collected by filtration to yield a brown solid that was recrystallized from i-PrOH/Et2O to
yield 0.09 g (39%) of 3b as a pale brown solid: mp 185 °C (lit.18 mp 178−181 °C, i-
PrOH/Et2O). 1H NMR (DMSO-d6) δ 1.42 (d, 3H, CH3), 2.57 (s, 3H, CH3), 5.18 (d, 1H,
CH), 7.57 (t, 1H, ArH), 7.95 (d, 1H, ArH), 8.02 (d, 1H, ArH), 8.19 (t, 1H, ArH), 9.16 (br s,
1H, NH), 9.62 (br s, 1H, NH+).
The following targets were prepared in the same manner as 3b.
1-(2-Chlorophenyl)-2-(methylamino)propan-1-one Hydrochloride (2a). The
product was obtained from bromopropiophenone 5a19 as a white solid in 35% yield after
recrystallization from MeOH/EtOAc: mp 172−174 °C (lit.20 mp 159−161 °C). 1H NMR
(DMSO-d6) δ 1.37 (d, 3H, CH3), 2.66 (s, 3H, CH3), 4.99 (q, 1H, CH), 7.55−7.59 (m, 1H,
+
ArH), 7.66 (d, 2H, ArH), 7.90 (d, 1H, ArH), 9.36 (br s, 2H, NH2 ); Due to the discrepancy
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 16 of 25
1
2
3
4
with the literature melting point, 2a was submitted for elemental analysis. Anal. Calcd for
5
6
(C10H12ClNO·HCl) C, 51.30; H, 5.60; N, 5.98. Found: C, 51.08; H, 5.51; N, 5.94.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1-(2-Bromophenyl)-2-(methylamino)propan-1-one Hydrochloride (2b). The
product was obtained from 5b21 as a white solid in 29% yield after recrystallization from
MeOH/EtOAc: mp 172−174 °C; 1H NMR (DMSO-d6) δ 1.36 (d, 3H, CH3), 2.66 (s, 3H,
CH3), 4.98 (q, 1H, CH), 7.54−7.62 (m, 2H, ArH), 7.82−7.84 (m, 1H, ArH), 7.88 (d, 1H,
+
ArH), 9.44 (br s, 2H, NH2 ); Anal. Calcd for (C10H12BrNO·HCl) C, 43.12; H, 4.70; N,
5.03. Found: C, 43.21; H, 4.84; N, 4.91.
2-(Methylamino)-1-(2-methylphenyl)propan-1-one Hydrochloride (2c). The
product was obtained from 5c19 as a white solid in 53% yield after recrystallization from
MeOH/EtOAc: mp 160 °C (lit.22 mp 163−165 °C). 1H NMR (DMSO-d6) δ 1.36 (d, 3H,
CH3), 2.44 (s, 3H, CH3), 2.62 (s, 3H, CH3), 5.06 (q, 1H, CH), 7.39−7.42 (m, 2H, ArH),
7.53−7.57 (m, 1H, ArH), 7.89−7.92 (m, 1H, ArH), 9.24 (br s, 1H, NH), 9.61 (br s, 1H,
NH+).
1-(2-Methoxyphenyl)-2-(methylamino)propan-1-one Hydrochloride (2d). The
product was obtained from 5d23 as a white solid in 70% yield after recrystallization from
MeOH/EtOAc: mp 184 °C (lit.23 mp 175−177 °C). 1H NMR (DMSO-d6) δ 1.40 (d, 3H,
CH3), 2.60 (s, 3H, CH3), 3.96 (s, 3H, CH3), 4.83 (q, 1H, CH), 7.13 (t, 1H, ArH), 7.28 (d,
+
1H, ArH), 7.70 (t, 1H, ArH), 7.80 (d, 1H, ArH), 9.22 (br s, 2H, NH2 ).
ACS Paragon Plus Environment

Page 17 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
2-(Methylamino)-1-(3-methylphenyl)propan-1-one Hydrochloride (3c). The
product was obtained from 6c24 as a grey solid in 70% yield after recrystallization from
MeOH/EtOAc: mp 193−195 °C (lit.22 mp 188−190 °C). 1H NMR (DMSO-d6) δ 1.42 (d,
3H, CH3), 2.39 (s, 3H, CH3), 2.57 (s, 3H, CH3), 5.13 (q, 1H, CH), 7.45−7.57 (m, 2H,
ArH), 7.81−7.85 (m, 2H, ArH).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2-(Methylamino)-1-(3-methoxyphenyl)propan-1-one Hydrochloride (3d). The
product was obtained from 6d25 as a white solid in 70% yield after recrystallization from
EtOH: mp 174−175 °C. 1H NMR (DMSO-d6) δ 1.42 (d, 3H, CH3), 2.57 (s, 3H, CH3), 3.83
(s, 3H, CH3), 5.17 (q, 1H, CH), 7.29–7.33 (m, 1H, ArH), 7.49–7.54 (m, 2H, ArH), 7.60–
+
7.63 (m, 1H, ArH), 9.34 (br s, 2H, NH2 ); Although the compound was previously
reported,26 it was not characterized. Anal. Calcd for (C11H15NO2·HCl·0.7 H2O) C, 54.52;
H, 7.24; N, 5.78. Found: C, 54.63; H, 7.20; N, 5.85.
2-(Methylamino)-1-(3-(trifluoromethyl)phenyl)propan-1-one Hydrochloride (3e).
The product was prepared from amine 8e22 and obtained as a yellow-white solid in 71%
yield after recrystallization from MeOH/EtOAc: mp 171 °C (lit.7 mp 163.5−165 °C). 1H
NMR (DMSO-d6) δ 1.54 (d, 3H, CH3), 2.70 (s, 3H, CH3), 5.38 (d, 1H, CH), 7.96 (t, 1H,
ArH), 8.22 (d, 1H, ArH), 8.42−8.43 (m, 2H, ArH), 9.28 (br s, 1H, NH), 9.76 (br s, 1H,
NH+).
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 18 of 25
1
2
3
4
5
6
7
8
9
In vitro release assay. Assays were performed as previously described.6 Male
Sprague-Dawley rats (Harlan Laboratories, Frederick, MD, USA) weighing 250-350 g
were housed three per cage with free access to food and water and maintained on a 12-
h light/dark cycle with lights on from 7:00 a.m. to 7:00 p.m. Animal facilities were
accredited by the Association for the Assessment and Accreditation of Laboratory
Animal Care, and procedures were carried out in accordance with the Institutional
Animal Care and Use Committee and the National Institutes of Health guidelines on
care and use of animal subjects in research (National Research Council.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Rats were euthanized by CO2 narcosis, and brains were processed to yield
synaptosomes. Synaptosomes were prepared from striatum for DAT assays, whereas
synaptosomes were prepared from whole brain minus striatum and cerebellum for the
NET and SERT assays. [3H]1-Methyl-4-phenylpyridinium ([3H]MPP+) (9 nM) was used
as the radiolabeled substrate for DAT and NET, whereas [3H]5-HT (5 nM) was used as
a substrate for SERT. All buffers used in the release assays contained 1 µM reserpine
to block vesicular uptake of substrates. The selectivity of assays was optimized for a
single transporter by including unlabeled compounds to prevent the uptake of [3H]MPP+
or [3H]5-HT by competing transporters. Synaptosomes were preloaded with
radiolabeled substrate in Krebs-phosphate buffer for 1 h (steady state). Assays were
initiated by adding 850 µL of preloaded synaptosomes to 150 µL of test drug. Assays
were terminated by vacuum filtration, and retained radioactivity was quantified by liquid
scintillation counting. Effects of test drug concentrations were expressed as %
Maximum Release, with maximum release (i.e., 100% Emax) defined as the release
ACS Paragon Plus Environment

Page 19 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
produced by 10 nM tyramine for DAT and NET assay conditions, and 100 nM tyramine
for SERT assay conditions. These concentrations of tyramine evoke the efflux of all
“releasable” tritium from synaptosomes as determined previously.27 EC50 values were
determined using nonlinear least-squares curve fitting (GraphPad Prism, v. 6.0;
GraphPad Scientific, San Diego, CA, USA).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Correlation analysis. The correlation shown as Figure 2 was obtained using the linear
regression analysis feature of GraphPad Prism, v. 7.01 (GraphPad Scientific, San
Diego, CA, USA). EC50 values in Table 1 were converted to their pEC50 values prior to
analysis.
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 20 of 25
1
2
3
4
REFERENCES
5
6
7
8
1.
Glennon, R. A. Bath salts, mephedrone, and methylenedioxypyrovalerone as
emerging illicit drugs that will need targeted therapeutic intervention. (2014) Adv.
Pharmacol. 69, 581–620.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2.
Baumann, M. H., Glennon, R. A., and Wiley, J. L. (Eds.), (2017)
Neuropharmacology of New Psychoactive Substances (NPS); The Science Behind
the Headlines. Springer International. Cham, Switzerland.
3.
4.
Glennon, R. A., and Dukat, M. (2017) Structure-activity relationships of synthetic
cathinones. Curr. Top. Behav. Neurosci. 32, 19–47.
Bonano, J. S., Banks, M. L., Kolanos, R., Sakloth, F., Barnier, M. L., Glennon, R.
A., Cozzi, N. V., Partilla, J. S., Baumann, M. H., and Negus, S.S. (2015)
Quantitative structure-activity relationship analysis of the pharmacology of para-
substituted methcathinone analogues. Br. J. Pharmacol. 172, 2433–2444.
Sakloth, F., Kolanos, R., Mosier, P. D., Bonano, J. S., Banks, M. L., Partilla, J. S.,
Baumann, M. H., Negus, S. S., and Glennon, R. A. (2015) Steric parameters,
molecular modeling and hydropathic interaction analysis of the pharmacology of
para-substituted methcathinone analogues. Br. J. Pharmacol. 172, 2210–2218.
Shalabi, A. R., Walther, D., Baumann, M.H., and Glennon, R. A. (2017)
Deconstructed analogues of bupropion reveal structural requirements for
transporter inhibition versus substrate-induced neurotransmitter release. ACS
Chem. Neurosci. 8, 1397–1403.
5.
6.
7.
Cozzi, N. V., Brandt, S. D.’ Daley, P. F., Partilla, J. S., Rothman, R. B., Tulzer,
A., Sitte, H. H., and Baumann, M. H. (2013) Pharmacological examination of
ACS Paragon Plus Environment

Page 21 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
trifluoromethyl ring-substituted methcathinone analogs. Eur. J. Pharmacol. 699,
180–187.
7
8
9
8.
9.
Odoardi, S., Romolo, F. S., and Strano-Rossi, S. (2016) A snapshot on NPS in
Italy: Distribution of drugs in seized materials analysed in an Italian forensic
laboratory in the period 2013-2015. Forensic Sci. Int. 265, 116–120.
Kohut, S., Fivel, P. A., Blough, B. E., Rothman, R. B., and Mello, N. K. (2013)
Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine
discrimination or self-administration in rhesus monkeys. Int. J.
Neuropsychopharmacol. 16, 1985–1998.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Meyer, M. R., Vollmar, C., Schwaninger, A. E., Wolf, E., and Maurer, H. H. (2012)
New cathinone-derived designer drugs 3-bromomethcathinone and 3-
fluoromethcathinone: studies on their metabolism in rat urine and human liver
microsomes using GC-MS and LC-high-resolution MS and their detectability
in urine. J. Mass. Spectrom. 47, 253–362.
11. Foley, K. F., and Cozzi, N. V. (2003) Novel aminopropiophenones as potential
antidepressants. Drug Dev. Res. 60, 252–260.
12. Adamowicz, P., Gieroń, J., Gil, D., Lechowicz, W., Skulska., and Tokarczyk, B.
(2016) The prevalence of new psychoactive substances in biological material – a
three-year review of casework in Poland. Drug Test. Anal. 8, 63–70.
13. Romanek, K., Stenzel, J., Schmoll, S., Schrettl, V., Geith, S., Eyer, F., and Rabe,
C. (2017) Synthetic cathinones in Southern Germany - characteristics of users,
substance-patterns, co-ingestions, and complications. Clin. Toxicol. (Phila) 55,
573–578.
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 22 of 25
1
2
3
4
5
6
7
8
9
14. European Drug Report (2017) European Monitoring Centre for Drugs and Drug
Addiction. Publications Office of the European Union, Luxembourg.
15. Luethi, D., Kolaczynska, K. E., Docci, L., Krähenbühl, S., Hoener, M. C., and
Liechti, M. E., (2018) Pharmacological profile of mephedrone analogs and related
new psychoactive substances. Neuropharmacology 134 (Part A), 4–12.
16. Backburg, M., Lindeman, E., Beck, O., and Helander, A. (2014) Characteristics of
analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA
project. Clin. Toxicol. 53, 46–53.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Carroll, F. I., Blough, B. E., and Abraham, P. Preparation of Arylaminoketones as
Monoamine Reuptake Inhibitors. WO 2010121022, October 21, 2010.
18. Foley, K. F. and Cozzi, N. V. (2003) Novel aminopropiophenones as potential
antidepressants. Drug Dev. Res. 60, 252–260.
19. Kalendra, D. M. and Sickles, B. R. (2003) Diminished reactivity of ortho-substituted
phenacyl bromides toward nucleophilic displacement. J. Org. Chem. 68, 1594–
1596.
20. Ose, S., Takamatsu, H., and Saheki, T. Alkanolamines. JP 36013215, November
30, 1960.
21. Elson, L. A., Gibson, C. S., and Johnson, J. D. A. (1930) o- and m-Derivatives of
simple alkyl phenyl ketones. J. Chem. Soc. 1128–1136.
22. Power, J. D., McGlynn, P., Clarke, K., McDermott, S. D., Kavanagh, P., and
O’Brien, J. (2011) The analysis of substituted cathinones. Part 1: chemical
analysis of 2-, 3- and 4-methylmethcathinones. Forensic Sci. Int. 212, 6–12.
ACS Paragon Plus Environment

Page 23 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
23. Heinzelmann, R. V. (1953) Physiologically active secondary amines. β-(o-
Methoxyphenyl)isopropyl-N-methylamine and related compounds. J. Am. Chem.
Soc. 75, 921–925.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24. Boss, C., Brotschi, C., Heidmann, B., Sifferlen, T., and Williams, J. T. 3,8-
Diazabicyclo[4.2.0]octane derivatives as orexin receptor antagonists and their
preparation and use for the treatment of diseases. WO 2012085857, June 28,
2012.
25. Carroll, F. I., Blough, B. E., Mascarella, S. W., Navaroo, H. A., Eaton, J. B., Lukas,
R. J., and Damaj, M.I. (2010) Synthesis and biological evaluation of bupropion
analogues as potential pharmacotherapies for smoking cessation. J. Med. Chem.
53, 2204–2214.
26. Awad, T., Clark, C. R., and DeRuiter, J. (2006) Chromatographic and mass
spectral studies on methoxymethcathinones related to 3,4-methylenedioxymeth-
amphetamine. J. Chromatogr. Sci. 44, 155–161.
27. Baumann, M. H., Partilla, J. S., Lehner, K. R., Thorndike, E. B., Hoffman, A. F.,
Holy, M., Rothman, R. B., Goldberg, S. R., Lupica, C. R., Sitte, H. H., Brandt, S.
D., Tella, S. R., Cozzi, N. V., and Schindler, C. W. (2013) Powerful cocaine-like
actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of
psychoactive ‘bath salts’ products. Neuropsychopharmacology 38, 552–562.
ACS Paragon Plus Environment

ACS Chemical Neuroscience
Page 24 of 25
1
2
3
4
5
6
7
8
9
AUTHOR INFORMATION
Corresponding Author
*email: glennon@vcu.edu
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ORCID
Richard A. Glennon: 0000-0002-3600-9045
Author contributions
ARS performed the synthesis under the direction of RAG, and DW measured
synaptosomal release under the supervision of MHB. RAG prepared the first draft of the
manuscript.
Funding
This work was supported in part by DA033930 and by the National Institute on Drug
Abuse Intramural Research Program Grant DA000523.
Notes
The authors declare no competing financial interest.
Supporting Information:
Effect of representative methcathinone analogs on transporter-mediated release via
DAT, NET, and SERT in rat brain synaptosomes, and steric parameters examined for
the 3-substituted methcathinone analogs.
ACS Paragon Plus Environment

Page 25 of 25
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
70x53mm (300 x 300 DPI)
ACS Paragon Plus Environment